Flavocure Biotech

Next Generation Therapeutic Solutions Inspired by Nature

What we do

Flavocure

Flavocure Biotech, Inc., is a biotechnology company focused on discovering and developing next-generation cures for patients. Our mission is to deliver transformative science to people with unmet/underserved medical needs, making a meaningful diﬀerence in patients’ lives.

Flavocure is currently developing a Theranostic platform targeting neurological diseases such as Alzheimer’s disease and Parkinson’s disease.

In addition, Flavocure is also targeting some aggressive and rare cancers, including pancreatic cancer and brain cancer.

Pipeline

Product	Target	Disease	Developmental Stage	Research Partners
Caflanone	CSF1-R & Kras	Pancreatic Cancer /Pancreatoblastoma	IND ready FDA-ORPHAN Drug Designation	Ongoing
	CSF1-R	GBM/Myeloma	Pre-Clinical	Ongoing
Caflanone / HLNT-06	CK2, CSF1-R	CNS	Pre-Clinical
		NanoCaflanone™ Platform
NCDx™	CSF1-R	CNS	Pre-Clinical
		Oncology	Pre-Clinical
NCThera™	Multiple targets	CNS	Pre-Clinical
		Oncology	Pre-Clinical

Our Research

NanoCaflanone™ Platform

Flavocure is advancing a proprietary Theranostic platform called NanoCaflanone™, designed to overcome the challenges of delivering drugs across the blood–brain barrier (BBB) to intracranial disease targets without the need for mechanical, chemical, or electrical alteration of the BBB.

NanoCaflanone™ targets disease-associated microglia (DAMs) directly impacting prevalent neurodegenerative diseases such as Alzheimer’s disease (AD) and AD Related Dementias (ADRD) such as Parkinson’s disease (PD), Lewy body dementias (LBD), Frontotemporal dementias (FTD), cerebral amyloid angiopathy (CAA), post traumatic brain injury (PTBI), chronic traumatic encephalopathy (CTE) and more.

The platform also targets tumor-associated microglia/macrophages (TAMMs) in the tumor microenvironment and has the potential to transform the diagnosis and treatment of several malignant brain tumors, such as glioblastoma multiforme (GBM) and brain metastases of some major cancers, including lung and breast cancers.

The diagnostic variant of NanoCaflanone™ NCDx, with proof-of-concept in AD and PD, represents a first-in-class, noninvasive molecular MRI probe.

By facilitating precision drug delivery, the NanoCaflanone™ platform aims to transform the diagnosis and management of brain disorders, particularly those driven by neuroinflammation.

In the US, SEER reported pancreatic cancer as the 11^th most common cancer with 60,430 new cases and 48,220 deaths in 2022. Pancreatic cancer statistics highlight a dire need for transformative therapies for this lethal disease

2022 US Pancreatic Cancer Statistics

New Cases: 60,430
Deaths: 48, 220
Accounts for 3% of all cancers, and 7% of all cancer deaths
5-year relative survival of 10.8%
Median Age at diagnosis: 70
Median age at death: 72

Glioblastoma or brain cancer is considered a very dire prognosis for patients. In the US, SEER reported cancers of the brain and other nervous systems to be 16^th most common cancer with 25,051 new cases and 18,280 deaths in 20222.

2022 Brain and other nervous system cancer statistics

New cases: 20,050
Deaths: 18,280
Accounts for 1.3% of all cancers, and 3% of all cancer deaths
5-year relative survival of 32.5%
Median age at diagnosis: 59
Median age at death: 66

Myeloma is a type of blood cancer that develops from plasma cells, a type of white blood cells. In the US, SEER reported Myeloma to be the 14^th most common cancer with 34,470 new cases and 12,640 deaths in 2022.

2022 Myeloma statistics

New cases: 34,470
Deaths: 12,640
Accounts for 1.8% of all cancers, and 2.1% of all cancer deaths
5-year relative survival of 57.9.5%
Median age at diagnosis: 69
Median age at death: 75

AML is a type of blood cancer that starts in the blood forming cells of the bone marrow. In the US SEER reported AML to be relatively rare cancer with 20,050 new cases and 11,540 deaths in 2022

2022 AML statistics